Sanofi Expands Respiratory Pipeline With Promising Asthma Data and New COPD Study Plans

Sanofi’s respiratory pipeline advances with new data in asthma and plans for new clinical studies in COPD New phase 2 data for amlitelimab show ...

April 15, 2025 | Tuesday | News
Lonza Joins CMAC to Advance Digital and Continuous Manufacturing Capabilities

Lonza joined CMAC to enhance its service offering for specialty and enhanced drug product and particle technologies   Lonza will ser...

April 15, 2025 | Tuesday | News
Roche Secures EU Approval for Columvi Combo as First Bispecific Antibody Regimen for Relapsed DLBCL

Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk of death compared to MabThe...

April 14, 2025 | Monday | Regulatory
FDA Clears argenx SE’s VYVGART Hytrulo Prefilled Syringe for Patient Self-Injection

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the U.S. Food a...

April 11, 2025 | Friday | News
Cellistic Introduces Echo™-NK Platform to Power Scalable Off-the-Shelf NK Cell Therapies for Cancer and Autoimmune Diseases

Cellistic, a pioneer in induced pluripotent stem cells (iPSC)-based cell therapies, is launching the Echo™-NK platform to enable the scalable manuf...

April 11, 2025 | Friday | News
Seegene Unveils Vision for Next-Gen PCR Automation with CURECA™ System

Seegene Inc., a global leader in molecular diagnostics (MDx), is advancing its vision for innovation in laboratory automation with the development of ...

April 10, 2025 | Thursday | News
AbbVie’s RINVOQ® Becomes First Oral JAK Inhibitor Approved in EU for Giant Cell Arteritis

AbbVie announced that the European Commission (EC) granted marketing authorization to RINVOQ® (upadacitinib; 15 mg, once daily) for the treatment ...

April 10, 2025 | Thursday | News
Idorsia’s Aprocitentan Demonstrates Efficacy in African American Patients with Resistant Hypertension

Idorsia Ltd  announced the publication of "Aprocitentan for Blood Pressure Reduction in Black Patients” in the April edition of Hypertensio...

April 10, 2025 | Thursday | News
AstraZeneca’s Imfinzi (Durvalumab) Gains European Union Approval for Resectable Non-Small Cell Lung Cancer Treatment

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been approved in the European Union (EU) for the treatment of adult...

April 07, 2025 | Monday | News
Cytiva Expands MabSelect Resin Portfolio to Advance Affordable and Scalable mAb Purification

  MabSelect SuRe 70 and MabSelect PrismA X resins to set new standards in affordability and productivity Cytiva's expanded resin portfolio will ...

April 03, 2025 | Thursday | News
Castle Biosciences to Present Key Data on DecisionDx-Melanoma at EADO 2025 Congress

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will share data via two poster presentations at the ...

April 02, 2025 | Wednesday | News
Lonza Launches New Operating Model to Power ‘One Lonza’ Vision and Streamline CDMO Business

Lonza’s new simplified and streamlined operating model is designed to support its One Lonza vision and strategy Previous divisional structure ...

April 02, 2025 | Wednesday | News
Regeneron and Sanofi Receive Approval for Dupixent® in Japan to Treat Chronic Obstructive Pulmonary Disease (COPD)

TARRYTOWN -- Regeneron Pharmaceuticals, and Sanofi announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan ...

March 31, 2025 | Monday | News
CHMP Recommends Opdivo® for EU Approval as Neoadjuvant and Adjuvant Treatment for Resectable NSCLC

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a...

March 31, 2025 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close